XML 57 R21.htm IDEA: XBRL DOCUMENT

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2014
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company evaluated subsequent events through the date on which these financial statements were issued and determined that no subsequent event constituted a matter that required adjustment to the financial statements for the nine months ended September 30, 2014. In October 2014, the Company entered into a purchase commitment with a contract manufacturer for approximately $700,000 for the manufacture of clinical batches of Ampligen®.